ChinaNationalAccordMedicinesCorporationLtd.
FirstQuarterlyReport2021
April2021
SectionI.ImportantNotesBoardofDirectorsandtheSupervisoryCommitteeofChinaNationalAccordMedicinesCorporationLtd.(hereinafterreferredtoastheCompany)anditsdirectors,supervisorsandseniorexecutivesshouldguaranteethereality,accuracyandcompletionofthequarterlyreport,therearenoanyfictitiousstatements,misleadingstatementsorimportantomissionscarriedinthisreport,andshalltakelegalresponsibilities,individualand/orjoint.AllDirectorsareattendedtheBoardMeetingforQuarterlyReportdeliberation.LinZhaoxiongpersoninchargeoftheCompany,GuGuolin,personinchargerofaccountingworksandWangYing,personinchargerofaccountingorgan(accountingofficer)herebyconfirmthattheFinancialReportofthisQuarterlyReportisauthentic,accurateandcomplete.
SectionII.Companyprofile
I.MainaccountingdataandfinancialindexesWhetherithasretroactiveadjustmentorre-statementonpreviousaccountingdata
□Yes√No
| CurrentPeriod | Sameperiodoflastyear | Changesofthisperiodoversameperiodoflastyear | |
| Operatingincome(RMB) | 16,049,966,325.75 | 12,824,196,278.66 | 25.15% |
| NetprofitattributabletoshareholdersofthelistedCompany(RMB) | 328,800,560.24 | 248,800,655.88 | 32.15% |
| Netprofitattributabletoshareholdersofthelistedcompanyafterdeductingnon-recurringgainsandlosses(RMB) | 321,593,612.98 | 241,724,850.95 | 33.04% |
| Netcashflowsfromoperatingactivities(RMB) | -306,748,999.24 | -688,273,848.63 | 55.43% |
| Basicearningspershare(RMB/Share) | 0.77 | 0.58 | 32.76% |
| Dilutedearningspershare(RMB/Share) | 0.77 | 0.58 | 32.76% |
| WeightedaverageROE | 2.33% | 1.92% | 0.41percentagepointup |
| Attheendofthereportingperiod | Attheendoflastyear | Changesofthisperiod-endoversameperiod-endoflastyear | |
| Totalassets(RMB) | 43,020,753,415.92 | 39,594,533,471.65 | 8.65% |
| Netassetsattributabletoshareholderoflistedcompany(RMB) | 14,277,162,387.04 | 13,948,322,652.33 | 2.36% |
Itemsofnon-recurringgainsandlosses
√Applicable□Notapplicable
InRMB
| Item | Amountfromyear-begintoperiod-end | Note |
| Gains/lossesfromthedisposalofnon-currentasset(includingthewrite-offthataccruedforimpairmentofassets) | 216,388.08 | Thegainsofdisposaloftheright-of-useassetsfromstoreleasesurrenderandthelossfromfixedassetsscrapping |
| Governmentalsubsidyreckonedintocurrentgains/losses(notincludingthesubsidyenjoyedinquotaorrationaccordingtonationalstandards,whicharecloselyrelevanttoenterprise’sbusiness) | 9,265,003.74 | VariousspecialsubsidiesandtaxrebatesreceivedinthePeriod |
| Switchbackofprovisionfordepreciationofaccountreceivableandcontractassetsthatareindividuallytestedforimpairment | 78,530.15 | |
| Othernon-operatingincomeandexpenditureexceptfortheaforementioneditems | 5,180,996.84 | Thenon-operatingincomearisingfromwrittenoffthemoneynotrequiredtobepaid |
| Othergains/lossessatisfyadefinitionofextraordinarygains/losses | 609,647.62 | |
| Less:Impactonincometax | 3,348,453.94 | |
| Impactonminorityshareholders’equity(post-tax) | 4,795,165.23 | |
| Total | 7,206,947.26 | -- |
Concerningtheextraordinaryprofit(gain)/lossdefinedbyQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,andtheitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,explainreasons
□Applicable√NotapplicableInreportingperiod,theCompanyhasnoparticularaboutitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss
II.Totalnumberofshareholdersattheendofthisreportperiodandtoptenshareholders
1.Totalnumberofcommonshareholdersattheendofthisreportperiodandtoptencommonshareholders
Inshares
| Totalcommonshareholdersattheendofreportperiod | 42,431 | Totalpreferenceshareholderswithvotingrightsrecoveredatendofreportingperiod(ifapplicable) | 0 | |||
| Toptenshareholders | ||||||
| Shareholder’sname | Natureofshareholder | Proportionofsharesheld | Amountofsharesheld | Amountofrestrictedsharesheld | Numberofsharepledged/frozen | |
| Stateofshare | Amount | |||||
| SinopharmGroupCo.,Ltd. | State-ownedlegalperson | 56.06% | 239,999,991 | 5,505,770 | ||
| HongKongSecuritiesClearingCompanyLtd | ForeignCorporation | 3.55% | 15,215,743 | |||
| FIRSTSENTIERINVESTORSGLOBALUMBRELLA | ForeignCorporation | 2.68% | 11,469,644 | |||
| FUNDPLC-FSSACHINAGROWTHFUND | ||||
| ChinaNationalPharmaceuticalForeignTradeCorp. | State-ownedlegalperson | 1.24% | 5,323,043 | |
| NationalSocialSecurityFund-portfolio413 | Domesticnonstate-ownedCorporation | 0.97% | 4,161,032 | |
| CentralHuijinInvestmentLtd. | State-ownedlegalperson | 0.89% | 3,804,400 | |
| BBHBOSS/AFIDELITYFD-CHINAFOCUSFD | ForeignCorporation | 0.78% | 3,358,761 | |
| CPICFund-ChinaPacificLifeInsuranceCo.,Lt.-participatinginsurance-CPICfundPICCStockRelativeIncome(guaranteedbonus)singleassetmanagementplan | Domesticnonstate-ownedCorporation | 0.66% | 2,822,801 | |
| FidelityInvestmentManagement(HongKong)Limited-Client’sfund | ForeignCorporation | 0.54% | 2,308,237 | |
| ChinaConstructionBankCo.,Ltd.-ChinaEuropeValueDiscoveryEquityFund | Domesticnonstate-ownedCorporation | 0.45% | 1,921,921 | |
| Toptenshareholderswithunrestrictedsharesheld | ||||
| Shareholder’sname | Amountofunrestrictedsharesheld | Typeofshares | |
| Type | Amount | ||
| SinopharmGroupCo.,Ltd. | 234,494,221 | RMBordinaryshares | 234,494,221 |
| HongKongSecuritiesClearingCompanyLtd | 15,215,743 | RMBordinaryshares | 15,215,743 |
| FIRSTSENTIERINVESTORSGLOBALUMBRELLAFUNDPLC-FSSACHINAGROWTHFUND | 11,469,644 | Domesticlistedforeignshares | 11,469,644 |
| ChinaNationalPharmaceuticalForeignTradeCorp. | 5,323,043 | RMBordinaryshares | 5,323,043 |
| NationalSocialSecurityFund-portfolio413 | 4,161,032 | RMBordinaryshares | 4,161,032 |
| CentralHuijinInvestmentLtd. | 3,804,400 | RMBordinaryshares | 3,804,400 |
| BBHBOSS/AFIDELITYFD-CHINAFOCUSFD | 3,358,761 | Domesticlistedforeignshares | 3,358,761 |
| CPICFund-ChinaPacificLifeInsuranceCo.,Lt.-participatinginsurance-CPICfundPICCStockRelativeIncome(guaranteedbonus)singleassetmanagementplan | 2,822,801 | RMBordinaryshares | 2,822,801 |
| FidelityInvestmentManagement(HongKong)Limited-Client’sfund | 2,308,237 | RMBordinaryshares | 2,308,237 |
| ChinaConstructionBankCo.,Ltd.-ChinaEuropeValueDiscoveryEquityFund | 1,921,921 | RMBordinaryshares | 1,921,921 |
| Explanationonassociatedrelationshipamongtheaforesaidshareholders | SinopharmGroupCo.,Ltd.andChinaNationalPharmaceuticalForeignTradeCorporationhavethesameactualcontroller,whichisChinaNationalPharmaceuticalGroupCorporation.ItisunknownthatthereexistsnoassociatedrelationshiporbelongstotheconsistentactionistamongtheothertradableshareholdersregulatedbytheManagementMeasureofInformationDisclosureonChangeofShareholdingforListedCompanies. | ||
Whethertoptencommonshareholdersortoptencommonshareholderswithun-restrictsharesheldhaveabuy-backagreementdealinginreportingperiod
□Yes√NoThetoptencommonshareholdersortoptencommonshareholderswithun-restrictsharesheldoftheCompanyhavenobuy-backagreementdealinginreportingperiod.
2.TotalshareholderswithpreferredstockheldatPeriod-endandsharesheldbytoptenshareholderswithpreferredstockheld
□Applicable√Notapplicable
SectionIII.SignificantEventsI.Particularsaboutmaterialchangesinitemsofmainaccountingstatementandfinancialindexandexplanationsofreasons
√Applicable□Notapplicable
1.Receivablefinancing:adecreaseof973.0057millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof-69.25%,mainlybecausethebankacceptancebilldiscountinthePeriodincreased;
2.Short-termborrowings:anincreaseof2335.6654millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof
144.88%,mainlybecausethesupplychainfinancingincreasedinthePeriod;
3.Employeebenefitspayable:adecreaseof115.9978millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof-32.47%,mainlybecausethesalariesandbonusaccruedinthepreviousyeararepaidinthePeriod;
4.Otherpayables:anincreaseof499.6124millionYuancomparedwiththebeginningoftheperiod,withagrowthrateof31.24%,mainlyduetotheequityconsiderationpayablearisingfromacquisitionofYunnanGuodaDishengDrugstoreChainCo.,LtdandYunnanGuodaDishengPharmacyCo.,ltdbysubsidiaryofthecompany-SinopharmHoldingGuodaDrugstoreCo.,Ltd.(hereinafterreferredtoasGuodaDrugstore),andthefactoringreturnofunrecoverableaccountreceivableincreasedinthePeriod;
5.Financecosts:anincreaseof21.6634millionYuanonayear-on-yearbasis,withagrowthrateof74.67%,mainlybecausepayingalargeamountofequityacquisitionconsiderationin2020,resultinginareductioninbankdeposit,andtheinterestfrombankdepositdeclinedcorrespondingly,andtheinterestexpensesonsupplychainfinancingincreasedonay-o-ybasis;
6.Investmentincome:anincreaseof48.6294millionYuanonayear-on-yearbasis,withagrowthrateof113.95%,mainlybecausetheinvestmentincomefromassociatedenterpriseincreasedfromayearearlier;
7.Impairmentlosses:anincreaseof1.8901millionYuanonayear-on-yearbasis,withagrowthrateof118.24%,mainlybecauseprovisionforfallingpriceofinventoriesincreasedonay-o-ybasis;
8.Gainondisposalofassets:anincreaseof0.5332millionYuanonayear-on-yearbasis,withagrowthrateof204.07%,mainlyduetothegainsofdisposaloftheright-of-useassetsfromretailstoreleasesurrender;
9.Non-operatingincome:anincreaseof4.5591millionYuanonayear-on-yearbasis,withagrowthrateof251.64%,mainlybecausewrittenoffthemoneynotrequiredtobepaidinthePeriod;
10.Non-operatingexpenses:adecreaseof1.1396millionYuanonayear-on-yearbasis,withagrowthrateof-66.63%,mainlybecausetheamercementoutlaydeclinedinthePeriod;
11.Netprofit:anincreaseof94.4755millionYuanonayear-on-yearbasis,withagrowthrateof32.02%,mainlybecauseoperationinthePeriodhasagrowthperformance,soaringoperationincomemakesthegrossprofitincreasedandtheinvestmentincomefromassociatedenterpriseincreasedfromayearearlier;
12.Profitorlossfromcontinuingoperations:anincreaseof94.4755millionYuanonayear-on-yearbasis,withagrowthrateof
32.02%,mainlybecauseoperationinthePeriodhasagrowthperformance,soaringoperationincomemakesthegrossprofitincreasedandtheinvestmentincomefromassociatedenterpriseincreasedfromayearearlier;
13.Netprofitattributabletoownersoftheparentcompany:anincreaseof79.9999millionYuanonayear-on-yearbasis,withagrowthrateof32.15%,mainlybecauseoperationinthePeriodhasagrowthperformance,soaringoperationincomemakesthegrossprofitincreasedandtheinvestmentincomefromassociatedenterpriseincreasedfromayearearlier;
14.Netprofitattributabletonon-controllinginterests:anincreaseof14.4755millionYuanonayear-on-yearbasis,withagrowthrateof31.27%,mainlybecausethesubsidiaryGuodaDrugstore’snetprofitattributabletotheownersoftheparentcompanyincreasedyear-on-year,correspondinglytheminorityshareholder’sgains/lossesattributabletothegroup’sstrategicinvestorWalgreensBootsAlliance(HongKong)InvestmentsLimited(hereinafterreferredtoas"WBA")increased;
15.Othercomprehensiveincome,netoftax:anincreaseof84,503.76Yuanonayear-on-yearbasis,withagrowthrateof100.00%,mainlybecauseothercomprehensiveincomeofassociateschangedduringthecurrentperiod;
16.Othercomprehensiveincomeattributabletoshareholdersofownersoftheparent,netoftax:anincreaseof84,503.76Yuanonayear-on-yearbasis,withagrowthrateof100.00%,mainlybecauseothercomprehensiveincomeofassociateschangedduringthecurrentperiod;
17.Othercomprehensiveincomethatmaybereclassifiedtoprofitorloss:anincreaseof84,503.76Yuanonayear-on-yearbasis,withagrowthrateof100.00%,mainlyduetotheothercomprehensiveincomeavailablefortransfertoprofit/lossarisingfromassociatesinthePeriod;
18.Totalcomprehensiveincome:anincreaseof94.56millionYuanonayear-on-yearbasis,withagrowthrateof32.04%,mainlyduetotherelativelygoodoperatinggrowthinthecurrentperiod,grossprofitincreasedforthesoaringoperationincome,andtheinvestmentincomefromassociatesincreasedonay-o-ybasis;
19.Totalcomprehensiveincomeattributabletoownersoftheparent:anincreaseof80.0844millionYuanonayear-on-yearbasis,withagrowthrateof32.19%,mainlyduetotherelativelygoodoperatinggrowthinthecurrentperiod,grossprofitincreasedforthesoaringoperationincome,andtheinvestmentincomefromassociatesincreasedonay-o-ybasis;
20.Totalcomprehensiveincomeattributabletonon-controllinginterests:anincreaseof14.4755millionYuanonayear-on-yearbasis,withagrowthrateof31.27%,mainlybecausethenetprofitattributabletoownersofparentcompanyfromsubsidiaryGuodaDrugstorehasanincreasedfromayearearlier,andcorrespondinglytheminorityshareholder’sgains/lossesattributabletothegroup’sstrategicinvestorWBAincreased;
21.Basicearningspershare:anincreaseof0.19Yuan/shareonayear-on-yearbasis,withagrowthrateof32.76%,mainlyduetotherelativelygoodoperatinggrowthinthecurrentperiod,grossprofitincreasedforthesoaringoperationincome,andtheinvestmentincomefromassociatesincreasedonay-o-ybasis,therefore,thenetprofitattributabletoshareholdersoflistedcompanyincreased
32.15%fromayearearlier,basicEPSgrowthcorrespondinglywith32.76%up;
22.Dilutedearningspershare:anincreaseof0.19Yuan/shareonayear-on-yearbasis,withagrowthrateof32.76%,mainlyduetotherelativelygoodoperatinggrowthinthecurrentperiod,grossprofitincreasedforthesoaringoperationincome,andtheinvestmentincomefromassociatesincreasedonay-o-ybasis,therefore,thenetprofitattributabletoshareholdersoflistedcompanyincreased
32.15%fromayearearlier,dilutedEPSgrowthcorrespondinglywith32.76%up;
23.Receiptsoftaxesandsurchargesrefunds:anincreaseof4.8427millionYuanonayear-on-yearbasis,withagrowthrateof
624.66%,mainlyduetothereceiptofoverpaidcorporateincometaxrebatesinpreviousyears;
24.Othercashreceiptsrelatingtooperatingactivities:adecreaseof223.6696millionYuanonayear-on-yearbasis,withagrowthrateof-51.61%,mainlyduetotheyear-on-yeardecreaseinspecialreservefundsreceivedinthisperiod;
25.Netcashflowsfromoperatingactivities:anincreaseof381.5248millionYuanonayear-on-yearbasis,withagrowthrateof
55.43%,mainlyduetotheincreaseinoperatingincome,thecashreceivedfromthesaleofgoodsandtheprovisionoflaborservicesincreasedaccordingly;
26.Cashreceiptsfromreturnsofinvestments:anincreaseof2.9974millionYuanonayear-on-yearbasis,withagrowthrateof
100.00%,mainlybecausethecompanyreceivedthewithdrawalfundsfromtheSinopharmZhongjinMedicalIndustryFundinvestmentprojectintheperiod,andtherewasnosuchmatterinthesameperiodlastyear;
27.Cashreceivedfromreturnsoninvestments:anincreaseof3.5996millionYuanonayear-on-yearbasis,withagrowthrateof
100.00%,mainlybecausethecompanyreceiveddividendsfromSinopharmZhongjinMedicalIndustryFundprojectinvestmentintheperiod,andtherewasnosuchmatterinthesameperiodlastyear;
28.Netcashreceiptsfromdisposaloffixedassets,intangibleassetsandotherlong-termassets:anincreaseof0.2197millionYuanonayear-on-yearbasis,withagrowthrateof204.49%,mainlyduetothecashreceivedfromthedisposaloffixedassetsincreasedintheperiod;
29.Othercashreceiptsrelatingtoinvestingactivities:adecreaseof22millionYuanonayear-on-yearbasis,withagrowthrateof-100.00%,mainlybecauseatsameperiodlastyear,thePudongNewAreaofShanghaiPharmaceuticalMedicineLtdwascombinedunderthesamecontrolbythesubsidiaryofthecompany-GuodaDrugstore,andrecoveryofthebalanceoriginallycollectedinthe
cashpoolofitsoriginalparentcompany,whiletherewasnosuchmatterinthecurrentperiod;
30.Totalcashinflowsfrominvestingactivities:adecreaseof15.1833millionYuanonayear-on-yearbasis,withagrowthrateof-68.68%,mainlybecauseatsameperiodlastyear,thePudongNewAreaofShanghaiPharmaceuticalMedicineLtdwascombinedunderthesamecontrolbythesubsidiaryofthecompany-GuodaDrugstore,andrecoveryofthebalanceoriginallycollectedinthecashpoolofitsoriginalparentcompany,whiletherewasnosuchmatterinthecurrentperiod;
31.Cashpaymentsforinvestments:anincreaseof15.7387millionYuanonayear-on-yearbasis,withagrowthrateof138.78%,mainlyduetotheyear-on-yearincreaseinthepaymentofstoreredemptionfeesbyGuodaDrugstore,asubsidiaryofthecompany;
32.Netcashpaymentsforacquisitionofsubsidiariesandotherbusinessunits:adecreaseof591.7232millionYuanonayear-on-yearbasis,withagrowthrateof-89.00%,mainlybecausepaymentfortheacquisitionofthesubsidiaryfromGuodaDrugstoreinthecurrentperiodhasdecreasedcomparedwiththesameperiodlastyear;
33.Othercashpaymentsrelatingtoinvestingactivities:adecreaseof41.3645millionYuanonayear-on-yearbasis,withagrowthrateof-100.00%,mainlybecausethepaymentofequityacquisitionforpreviousyearhasbeenpaidatsameperiodlastyear,whiletherewasnosuchmatterinthisperiod;
34.Totalcashoutflowsfrominvestingactivities:adecreaseof605.5959millionYuanonayear-on-yearbasis,withagrowthrateof-78.87%,mainlybecausepaymentfortheacquisitionofthesubsidiaryfromGuodaDrugstoreinthecurrentperiodhasdecreasedcomparedwiththesameperiodlastyear;
35.Netcashflowfrominvestmentactivities:anincreaseof590.4126millionYuanonayear-on-yearbasis,withagrowthrateof
79.18%,mainlybecausepaymentfortheacquisitionofthesubsidiaryfromGuodaDrugstoreinthecurrentperiodhasdecreasedcomparedwiththesameperiodlastyear;
36.Cashproceedsfrominvestmentsbyothers:anincreaseof5.88millionYuanonayear-on-yearbasis,withagrowthrateof
100.00%,mainlyduetothereceiptofinvestmentfundsfromminorityshareholdersinthisperiod,whiletherewasnosuchmatterinthesameperiodlastyear;
37.Cashreceivedfromborrowing:anincreaseof281.1937millionYuanonayear-on-yearbasis,withagrowthrateof98.25%,mainlybecausethebankloansreceivedduringthecurrentperiodincreased;
38.Totalcashinflowsfromfinancingactivities:anincreaseof247.4363millionYuanonayear-on-yearbasis,withagrowthrateof
39.70%,mainlybecausethebankloansreceivedduringthecurrentperiodincreased;
39.Othercashpaymentsrelatingtofinancingactivities:adecreaseof227.8233millionYuanonayear-on-yearbasis,withagrowthrateof-48.10%,mainlyduetotheinvestmentamountpaidformergerthePudongNewAreaofShanghaiPharmaceuticalMedicineLtdunderthesamecontrolbythesubsidiaryofthecompany-GuodaDrugstoreatsameperiodlastyear,whiletherewasnosuchmatterinthecurrentperiod;
40.Netcashflowsfromfinancingactivities:anincreaseof445.6404millionYuanonayear-on-yearbasis,withagrowthrateof
780.23%,mainlybecausebankloansreceivedinthePeriodincreasedandatsameperiodlastyear,theinvestmentamountarepaidforcombinedthePudongNewAreaofShanghaiPharmaceuticalMedicineLtdunderthesamecontrolbyGuodaDrugstore,therewasnosuchmatterinthecurrentperiod;
41.Effectofexchangeratechangesoncashandcashequivalents:adecreaseof2,805.98Yuanonayear-on-yearbasis,withagrowthrateof-768.34%,mainlyduetotheimpactofexchangeratechanges;
42.Netincreaseincashandcashequivalents:anincreaseof1,417.5751millionYuanonayear-on-yearbasis,withagrowthrateof
95.07%,mainlyduetotheincreaseinoperatingincome,thecashreceivedfromthesaleofgoodsandtheprovisionoflaborservicesincreasedaccordingly;andthepaymentforsubsidiaryacquisitionfromsubsidiaryGuodaDrugstoredeclinedfromayearearlier.
43.Cashandcashequivalentsatbeginningoftheyear:adecreaseof3,020.9579millionYuanonayear-on-yearbasis,withagrowthrateof-35.85%,mainlybecausethecompanypaidalargeamountofequitypurchaseconsiderationin2020,resultinginadecreaseinthebalanceofcashandcashequivalentsatthebeginningoftheyear.
II.Analysisandexplanationofsignificanteventsandtheirinfluenceandsolutions
□Applicable√NotapplicableProgressofsharesbuy-back
□Applicable√NotapplicableImplementationprogressofthereductionofrepurchasessharesbycentralizedbidding
□Applicable√Notapplicable
III.CommitmentscompletedinPeriodandthosewithoutcompletedtillendofthePeriodfromactualcontroller,shareholders,relatedparties,purchaserandcompanies
□Applicable√NotapplicableTheCompanyhasnocommitmentscompletedinPeriodandthosewithoutcompletedtillendofthePeriodfromactualcontroller,shareholders,relatedparties,purchaserandcompanies.IV.Financialassetinvestment
1.Securitiesinvestment
□Applicable√NotapplicableNosecurityinvestmentinthePeriod.
2.Derivativeinvestment
□Applicable√NotapplicableNoderivativeinvestmentinthePeriod.V.Progressofinvestmentprojectswithraisedfunds
□Applicable√Notapplicable
VI.PredictionofbusinessperformancefromJanuary–June2021Estimationonaccumulativenetprofitfromthebeginningoftheyeartotheendofnextreportperiodtobelossprobablyorthewarningofitsmaterialchangecomparedwiththecorrespondingperiodofthelastyearandexplanationonreason
□Applicable√NotapplicableVII.Majorcontractsfordailyoperations
□Applicable√NotapplicableVIII.Trustfinancing
□Applicable√Notapplicable
NotrustfinancinginthePeriod.
IX.Guaranteeoutsideagainsttheregulation
□Applicable√NotapplicableTheCompanyhadnoguaranteeoutsideagainsttheregulationintheperiod.
X.Non-operationalfundoccupationfromcontrollingshareholdersanditsrelatedparty
□Applicable√NotapplicableTheCompanyhadnonon-operationalfundoccupationformcontrollingshareholdersanditsrelatedpartyintheperiod.
XI.Registrationformforreceivingresearch,communicationandinterviewinthereportperiod
□Applicable√NotapplicableTheCompanyhadnoreceivingresearch,communicationorinterviewinthereportperiod.
SectionIV.FinancialStatementI.FinancialStatement
1.ConsolidateBalanceSheet
PreparedbyChinaNationalAccordMedicinesCorporationLtd.
March31,2021
InRMB
| Item | March31,2021 | December31,2020 |
| Currentassets: | ||
| Cashandbankbalances | 5,840,135,730.11 | 5,998,204,295.87 |
| Settlementprovisions | ||
| Capitallent | ||
| Tradingfinancialassets | ||
| Derivativefinancialassets | ||
| Notesreceivable | 607,883,873.14 | 622,115,477.04 |
| Accountsreceivable | 16,780,830,492.03 | 13,799,971,014.22 |
| Receivablefinancing | 431,981,996.92 | 1,404,987,700.38 |
| Advancestosuppliers | 590,101,876.56 | 480,313,574.71 |
| Insurancereceivable | ||
| Reinsurancereceivables | ||
| Contractreserveofreinsurancereceivable | ||
| Otherreceivables | 628,399,715.32 | 535,228,747.69 |
| Including:Interestreceivable | ||
| Dividendreceivable | ||
| Buyingbackthesaleoffinancialassets | ||
| Inventories | 7,219,060,669.89 | 6,285,010,674.46 |
| Contractassets | 15,417,457.50 | 15,177,731.64 |
| Assetsheldforsale | ||
| Non-currentassetduewithinoneyear | ||
| Othercurrentassets | 123,484,117.46 | 121,082,863.45 |
| Totalcurrentassets | 32,237,295,928.93 | 29,262,092,079.46 |
| Non-currentassets: | ||
| Loansandpaymentsonbehalf | ||
| Debtinvestment | ||
| Otherdebtinvestment | ||
| Long-termaccountreceivable | ||
| Long-termequityinvestment | 2,379,500,628.90 | 2,287,019,627.99 |
| Otherequityinstrumentinvestment | 99,488,340.28 | 99,488,340.28 |
| Othernon-currentfinancialassets | 117,974,908.51 | 120,972,350.24 |
| Investmentproperties | 125,907,819.38 | 127,444,379.94 |
| Fixedassets | 843,319,270.30 | 854,191,083.27 |
| Constructioninprogress | 49,119,148.89 | 46,631,190.23 |
| Productivebiologicalasset | ||
| Oilandgasasset | ||
| Right-of-useassets | 2,410,848,611.31 | 2,356,952,392.99 |
| Intangibleassets | 722,392,930.27 | 734,345,179.40 |
| ExpenseonResearchandDevelopment | ||
| Goodwill | 2,975,269,022.11 | 2,747,375,281.11 |
| Long-termprepaidexpenses | 489,002,945.70 | 457,705,276.09 |
| Deferredtaxassets | 97,737,555.41 | 92,118,767.81 |
| Othernon-currentasset | 472,896,305.93 | 408,197,522.84 |
| Totalnon-currentasset | 10,783,457,486.99 | 10,332,441,392.19 |
| Totalassets | 43,020,753,415.92 | 39,594,533,471.65 |
| Currentliabilities: | ||
| Short-termborrowings | 3,947,852,429.69 | 1,612,187,020.12 |
| Loanfromcentralbank | ||
| Capitalborrowed | ||
| Tradingfinancialliability | ||
| Derivativefinancialliability | ||
| Notespayable | 6,411,005,653.20 | 7,520,165,274.69 |
| Accountspayable | 9,161,357,988.53 | 7,697,451,142.50 |
| Receiptsinadvance | 10,089,304.61 | 12,352,466.64 |
| Contractliabilities | 382,788,595.61 | 368,600,357.14 |
| Sellingfinancialassetofrepurchase | ||
| Absorbingdepositandinterbankdeposit | ||
| Securitytradingofagency | ||
| Securitysalesofagency | ||
| Employeebenefitspayable | 241,214,266.47 | 357,212,047.10 |
| Taxpayable | 262,688,620.52 | 316,867,149.16 |
| Otherpayables | 2,098,779,260.44 | 1,599,166,881.14 |
| Including:Interestpayable | 25,916,885.64 | 35,572,620.82 |
| Dividendpayable | 6,389,320.96 | 6,389,320.96 |
| Commissionchargeandcommissionpayable | ||
| Reinsurancepayable | ||
| Liabilityheldforsale | ||
| Non-currentliabilitiesduewithinoneyear | 767,942,185.69 | 748,732,059.89 |
| Othercurrentliabilities | 27,334,439.97 | 24,787,078.55 |
| Totalcurrentliabilities | 23,311,052,744.73 | 20,257,521,476.93 |
| Non-currentliabilities: | ||
| Insurancecontractreserve | ||
| Long-termborrowings | 31,637,173.89 | 31,637,173.89 |
| Bondspayable | ||
| Including:Preferredstock | ||
| Perpetualcapitalsecurities | ||
| Leaseliabilities | 1,304,731,241.22 | 1,303,054,163.90 |
| Long-termpayables | 6,938,189.00 | 6,938,189.00 |
| Long-termemployeebenefitspayable | 1,319,000.00 | 1,319,000.00 |
| Provisions | 68,808,166.79 | 68,808,166.79 |
| Deferredincome | 94,199,523.33 | 89,843,583.37 |
| Deferredtaxliabilities | 201,334,176.46 | 205,921,408.66 |
| Othernon-currentliabilities | 675,330,586.26 | 740,862,989.59 |
| Totalnon-currentliabilities | 2,384,298,056.95 | 2,448,384,675.20 |
| Totalliabilities | 25,695,350,801.68 | 22,705,906,152.13 |
| Owner’sequity: | ||
| Sharecapital | 428,126,983.00 | 428,126,983.00 |
| Otherequityinstrument | ||
| Including:Preferredstock | ||
| Perpetualcapitalsecurities | ||
| Capitalsurplus | 4,372,458,724.43 | 4,372,504,053.72 |
| Less:Inventoryshares | ||
| Othercomprehensiveincome | 38,567,521.48 | 38,483,017.72 |
| Reasonablereserve | ||
| Surplusreserve | 214,063,491.50 | 214,063,491.50 |
| Provisionofgeneralrisk | ||
| Retainedearnings | 9,223,945,666.63 | 8,895,145,106.39 |
| Totalequityattributabletoownersoftheparent | 14,277,162,387.04 | 13,948,322,652.33 |
| Non-controllinginterests | 3,048,240,227.20 | 2,940,304,667.19 |
| Totalequity | 17,325,402,614.24 | 16,888,627,319.52 |
| Totalliabilitiesandequity | 43,020,753,415.92 | 39,594,533,471.65 |
LegalRepresentative:LinZhaoxiongPersoninchargeofaccountingworks:GuGuolinPersoninchargeofaccountinginstitute:WangYing
2.BalanceSheetofParentCompany
InRMB
| Item | March31,2021 | December31,2020 |
| Currentassets: | ||
| Cashandbankbalances | 2,918,160,838.33 | 3,020,909,473.71 |
| Tradingfinancialassets | ||
| Derivativefinancialassets | ||
| Notesreceivable | 27,981,836.47 | 30,984,449.44 |
| Accountsreceivable | 682,802,750.34 | 609,575,301.13 |
| Receivablesfinancing | 18,049,841.43 | 30,248,631.32 |
| Advancestosuppliers | 3,878,976.70 | 6,722,204.59 |
| Otherreceivables | 3,762,424,972.63 | 3,562,309,346.07 |
| Including:Interestreceivable | ||
| Dividendreceivable | ||
| Inventories | 217,381,506.64 | 172,275,777.63 |
| Contractassets | 127,994.54 | 139,154.54 |
| Assetsheldforsale | ||
| Non-currentassetsmaturingwithinoneyear | ||
| Othercurrentassets | 39,482.38 | 39,482.38 |
| Totalcurrentassets | 7,630,848,199.46 | 7,433,203,820.81 |
| Non-currentassets: | ||
| Debtinvestment | ||
| Otherdebtinvestment | ||
| Long-termreceivables | ||
| Long-termequityinvestments | 7,965,880,218.99 | 7,873,668,245.16 |
| Investmentinotherequityinstrument | ||
| Othernon-currentfinancialassets | 117,974,908.51 | 120,972,350.24 |
| Investmentproperties | 1,444,115.41 | 1,452,132.04 |
| Fixedassets | 12,387,613.23 | 13,279,902.76 |
| Constructioninprogress | ||
| Productivebiologicalassets | ||
| Oilandnaturalgasassets | ||
| Right-of-useassets | 4,863,467.72 | 5,142,755.88 |
| Intangibleassets | 4,687,410.11 | 4,622,268.00 |
| Researchanddevelopmentcosts | ||
| Goodwill | ||
| Long-termdeferredexpenses | 4,102,834.80 | 4,335,802.92 |
| Deferredtaxassets | 9,218,485.21 | 9,025,057.52 |
| Othernon-currentassets | 12,304,025.21 | 12,967,715.50 |
| Totalnon-currentassets | 8,132,863,079.19 | 8,045,466,230.02 |
| Totalassets | 15,763,711,278.65 | 15,478,670,050.83 |
| Currentliabilities | ||
| Short-termborrowings | 739,174,743.69 | 157,892,942.24 |
| Tradingfinancialliability |
| Derivativefinancialliability | ||
| Notespayable | 295,146,453.96 | 756,364,719.49 |
| Accountspayable | 417,332,303.36 | 407,275,713.49 |
| Accountsreceivedinadvance | ||
| Contractliabilities | 8,613,252.72 | 1,807,562.61 |
| Employeebenefitspayable | 25,041,540.04 | 36,672,344.48 |
| Taxpayables | 17,831,732.43 | 13,975,905.04 |
| Otherpayables | 3,204,307,483.05 | 3,167,152,583.28 |
| Including:Interestpayable | 217,961.01 | 170,214.19 |
| Dividendpayable | ||
| Liabilityheldforsale | ||
| Non-currentliabilitiesduewithinoneyear | 1,067,368.38 | 1,056,120.58 |
| Othercurrentliabilities | 1,484,550.54 | 636,200.63 |
| Totalcurrentliabilities | 4,709,999,428.17 | 4,542,834,091.84 |
| Non-currentliabilities: | ||
| Long-termborrowings | 31,637,173.89 | 31,637,173.89 |
| Bondspayable | ||
| Including:preferredstock | ||
| Perpetualcapitalsecurities | ||
| Leaseliabilities | 4,184,170.00 | 4,455,967.97 |
| Long-termpayables | 800,000.00 | 800,000.00 |
| Longtermemployeecompensationpayable | ||
| Accruedliabilities | ||
| Deferredincome | 715,398.06 | 827,658.18 |
| Deferredincometaxliabilities | ||
| Othernon-currentliabilities | 10,538.58 | 11,042.52 |
| Totalnon-currentliabilities | 37,347,280.53 | 37,731,842.56 |
| Totalliabilities | 4,747,346,708.70 | 4,580,565,934.40 |
| Owners’equity: | ||
| Sharecapital | 428,126,983.00 | 428,126,983.00 |
| Otherequityinstrument | ||
| Including:preferredstock |
| Perpetualcapitalsecurities | ||
| Capitalsurplus | 4,467,946,102.30 | 4,467,991,431.59 |
| Less:Inventoryshares | ||
| Othercomprehensiveincome | -43,529.56 | -128,033.32 |
| Specialreserve | ||
| Surplusreserve | 214,063,491.50 | 214,063,491.50 |
| Retainedearnings | 5,906,271,522.71 | 5,788,050,243.66 |
| Totalshareholders’equity | 11,016,364,569.95 | 10,898,104,116.43 |
| Totalliabilitiesandshareholders’equity | 15,763,711,278.65 | 15,478,670,050.83 |
3.ConsolidatedProfitStatement
InRMB
| Item | Currentperiod | Lastperiod |
| I.Totaloperatingincome | 16,049,966,325.75 | 12,824,196,278.66 |
| Including:Operatingrevenue | 16,049,966,325.75 | 12,824,196,278.66 |
| Interestincome | ||
| Insurancegained | ||
| Commissionchargeandcommissionincome | ||
| II.Totaloperatingcost | 15,663,170,079.60 | 12,488,521,944.35 |
| Including:Operatingcost | 14,260,591,404.46 | 11,370,970,742.96 |
| Interestexpense | ||
| Commissionchargeandcommissionexpense | ||
| Cashsurrendervalue | ||
| Netamountofexpenseofcompensation | ||
| Netamountofwithdrawalofinsurancecontractreserve | ||
| Bonusexpenseofguaranteeslip | ||
| Reinsuranceexpense | ||
| Taxandsurcharges | 33,744,327.20 | 29,109,421.79 |
| Sellingexpenses | 1,080,543,941.75 | 844,624,826.78 |
| Administrativeexpense | 237,615,927.36 | 214,805,866.61 |
| R&Dexpense | ||
| Financecosts | 50,674,478.83 | 29,011,086.21 |
| Including:Interestexpense | 68,683,688.49 | 60,067,901.98 |
| Interestincome | 18,058,735.03 | 29,094,889.11 |
| Add:otherincome | 13,655,624.72 | 13,133,111.50 |
| Investmentincome(Lossislistedwith“-”) | 91,305,476.74 | 42,676,071.54 |
| Including:Investmentincomefromassociates | 92,441,826.44 | 60,020,272.13 |
| Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcost(Lossislistedwith“-”) | -4,735,905.31 | -18,342,866.43 |
| Exchangeincome(Lossislistedwith“-”) | ||
| Netexposurehedgingincome(Lossislistedwith“-”) | ||
| Incomefromchangeoffairvalue(Lossislistedwith“-”) | ||
| Creditimpairmentlosses(Lossislistedwith“-”) | -17,197,080.80 | -16,845,052.13 |
| Impairmentlosses(Lossislistedwith“-”) | -3,488,500.85 | -1,598,436.71 |
| Gainondisposalofassets(Lossislistedwith“-”) | 271,889.26 | -261,264.83 |
| III.Operatingprofit(Lossislistedwith“-”) | 471,343,655.22 | 372,778,763.68 |
| Add:Non-operatingincome | 6,370,834.89 | 1,811,729.05 |
| Less:Non-operatingexpense | 570,737.09 | 1,710,329.13 |
| IV.Totalprofit | 477,143,753.02 | 372,880,163.60 |
| Less:Incometaxexpense | 87,580,022.00 | 77,791,885.48 |
| V.Netprofit(Netlossislistedwith“-”) | 389,563,731.02 | 295,088,278.12 |
| (i)Classifybybusinesscontinuity | ||
| 1.Profitorlossfromcontinuingoperations | 389,563,731.02 | 295,088,278.12 |
| 2.terminationofnetprofit(netlosslistedwith‘-”) | ||
| (ii)Classifybyownership | ||
| 1.Netprofitattributabletoownersoftheparent | 328,800,560.24 | 248,800,655.88 |
| 2.Non-controllinginterests | 60,763,170.78 | 46,287,622.24 |
| VI.Othercomprehensiveincome,netoftax | 84,503.76 | |
| Othercomprehensiveincomeattributabletoshareholdersofownersoftheparent,netoftax | 84,503.76 | |
| (i)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
| 1.Changesofthedefinedbenefitplansthatre-measured | ||
| 2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss | ||
| 3.Changeoffairvalueofinvestmentinotherequityinstrument | ||
| 4.Fairvaluechangeofenterprise'screditrisk | ||
| 5.Other | ||
| (ii)Othercomprehensiveincomethatmaybereclassifiedtoprofitorloss | 84,503.76 | |
| 1.Othercomprehensiveincomeusingtheequitymethodthatmaybereclassifiedtoprofitorloss | 84,503.76 | |
| 2.Changeoffairvalueofotherdebtinvestment | ||
| 3.Amountoffinancialassetsre-classifytoothercomprehensiveincome | ||
| 4.Creditimpairmentprovisionforotherdebtinvestment | ||
| 5.Cashflowhedgingreserve | ||
| 6.Translationdifferencesarisingontranslationofforeigncurrency |
| financialstatements | ||
| 7.Other | ||
| Netafter-taxofothercomprehensiveincomeattributabletominorityshareholders | ||
| VII.Totalcomprehensiveincome | 389,648,234.78 | 295,088,278.12 |
| Totalcomprehensiveincomeattributabletoownersoftheparent | 328,885,064.00 | 248,800,655.88 |
| Totalcomprehensiveincomeattributabletonon-controllinginterests | 60,763,170.78 | 46,287,622.24 |
| VIII.Earningspershare: | ||
| (i)Basicearningspershare | 0.77 | 0.58 |
| (ii)Dilutedearningspershare | 0.77 | 0.58 |
EnterprisecombineunderthesamecontrolinthePeriod,thecombinedpartyrealizednetprofitof0Yuanbeforecombination,andrealized0YuanatlastperiodforcombinedpartyLegalRepresentative:LinZhaoxiongPersoninchargeofaccountingworks:GuGuolinPersoninchargeofaccountinginstitute:WangYing
4.ProfitStatementofParentCompany
InRMB
| Item | Currentperiod | Lastperiod |
| I.Operatingrevenue | 1,031,796,119.30 | 883,090,683.07 |
| Less:Operatingcosts | 991,971,454.23 | 850,760,365.77 |
| Taxesandsurcharge | 1,161,587.51 | 1,011,193.50 |
| Sellingexpenses | 16,856,699.35 | 16,302,891.84 |
| Administrativeexpenses | 20,817,040.62 | 22,374,408.72 |
| R&Dexpenses | ||
| Financecosts | -29,303,964.67 | -22,842,676.94 |
| Including:interestexpense | 10,689,978.60 | 9,151,290.82 |
| Interestincome | 40,183,409.94 | 32,061,791.21 |
| Add:otherincome | 401,103.90 | 293,056.51 |
| Investmentincome(Lossislistedwith“-”) | 95,583,979.88 | 60,592,685.27 |
| Including:InvestmentincomeonaffiliatedCompanyandjointventure | 92,172,799.36 | 60,134,457.45 |
| Incomefromthederecognitionoffinancialassetsmeasuredatamortisedcost(Lossislistedwith“-”) | -188,375.09 | -540,438.02 |
| Netexposurehedgingincome(Lossislistedwith“-”) | ||
| Changingincomeoffairvalue(Lossislistedwith“-”) | ||
| Creditimpairmentlosses(Lossislistedwith“-”) | -973,888.89 | |
| Impairmentlosses(Lossislistedwith“-”) | -561,173.91 | 217,422.14 |
| Gainondisposalofassets(Lossislistedwith“-”) | 22,815.68 | |
| II.Operatingprofit(Lossislistedwith“-”) | 125,740,027.81 | 75,613,775.21 |
| Add:Non-operatingincome | 1,645.98 | 1,578.11 |
| Less:Non-operatingexpense | ||
| III.TotalProfit(Lossislistedwith“-”) | 125,741,673.79 | 75,615,353.32 |
| Less:Incometaxexpense | 7,520,394.74 | 3,620,557.51 |
| IV.Netprofit(Netlossislistedwith“-”) | 118,221,279.05 | 71,994,795.81 |
| (i)Profitorlossfromcontinuingoperations(netlosslistedwith‘-”) | 118,221,279.05 | 71,994,795.81 |
| (ii)terminationofnetprofit(netlosslistedwith‘-”) | ||
| V.Othercomprehensiveincome,netoftax | 84,503.76 | |
| (i)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
| 1.Changesofthedefinedbenefitplansthatre-measured | ||
| 2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss |
| 3.Changeoffairvalueofinvestmentinotherequityinstrument | ||
| 4.Fairvaluechangeofenterprise'screditrisk | ||
| 5.Other | ||
| (ii)Othercomprehensiveincomethatmaybereclassifiedtoprofitorloss | 84,503.76 | |
| 1.Othercomprehensiveincomeusingtheequitymethodthatmaybereclassifiedtoprofitorloss | 84,503.76 | |
| 2.Changeoffairvalueofotherdebtinvestment | ||
| 3.Amountoffinancialassetsre-classifytoothercomprehensiveincome | ||
| 4.Creditimpairmentprovisionforotherdebtinvestment | ||
| 5.Cashflowhedgingreserve | ||
| 6.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
| 7.Other | ||
| VI.Totalcomprehensiveincome | 118,305,782.81 | 71,994,795.81 |
| VII.Earningspershare: | ||
| (i)Basicearningspershare | ||
| (ii)Dilutedearningspershare |
5.ConsolidatedCashFlowStatement
InRMB
| Item | Currentperiod | Lastperiod |
| I.Cashflowsfromoperatingactivities: | ||
| Cashreceivedfromsalesofgoodorrenderingofservices | 15,194,724,502.12 | 13,201,992,638.81 |
| Netincreaseofcustomerdepositandinterbankdeposit | ||
| Netincreaseofloanfromcentral |
| bank | ||
| Netincreaseofcapitalborrowedfromotherfinancialinstitution | ||
| Cashreceivedfromoriginalinsurancecontractfee | ||
| Netcashreceivedfromreinsurancebusiness | ||
| Netincreaseofinsuredsavingsandinvestment | ||
| Cashreceivedfrominterest,commissionchargeandcommission | ||
| Netincreaseofcapitalborrowed | ||
| Netincreaseofreturnedbusinesscapital | ||
| Netcashreceivedbyagentsinsaleandpurchaseofsecurities | ||
| Receiptsoftaxesandsurchargesrefunds | 5,617,976.11 | 775,261.38 |
| Othercashreceiptsrelatingtooperatingactivities | 209,745,502.46 | 433,415,062.71 |
| Totalcashinflowsfromoperatingactivities | 15,410,087,980.69 | 13,636,182,962.90 |
| Cashpaymentsforgoodsandservices | 14,094,028,880.65 | 12,827,089,312.11 |
| Netincreaseofcustomerloansandadvances | ||
| Netincreaseofdepositsincentralbankandinterbank | ||
| Cashpaidfororiginalinsurancecontractcompensation | ||
| Netincreaseofcapitallent | ||
| Cashpaidforinterest,commissionchargeandcommission | ||
| Cashpaidforbonusofguaranteeslip | ||
| Cashpaymentstoandonbehalfofemployees | 894,497,321.19 | 703,922,606.95 |
| Paymentsofalltypesoftaxesand | 354,054,737.85 | 368,976,475.15 |
| surcharges | ||
| Othercashpaymentsrelatingtooperatingactivities | 374,256,040.24 | 424,468,417.32 |
| Totalcashoutflowsfromoperatingactivities | 15,716,836,979.93 | 14,324,456,811.53 |
| Netcashflowsfromoperatingactivities | -306,748,999.24 | -688,273,848.63 |
| II.Cashflowsfrominvestingactivities: | ||
| Cashreceiptsfromreturnsofinvestments | 2,997,441.73 | |
| Cashreceivedfromreturnsoninvestments | 3,599,555.61 | |
| Netcashreceiptsfromdisposaloffixedassets,intangibleassetsandotherlong-termassets | 327,119.50 | 107,430.91 |
| Netcashreceivedfromdisposalofsubsidiariesandotherunits | ||
| Othercashreceiptsrelatingtoinvestingactivities | 22,000,000.00 | |
| Totalcashinflowsfrominvestingactivities | 6,924,116.84 | 22,107,430.91 |
| Cashpaymentstoacquirefixedassets,intangibleassetsandotherlong-termassets | 61,960,648.98 | 50,207,587.50 |
| Cashpaymentsforinvestments | 27,079,733.00 | 11,341,032.15 |
| Netincreaseofmortgagedloans | ||
| Netcashpaymentsforacquisitionofsubsidiariesandotherbusinessunits | 73,159,498.29 | 664,882,681.20 |
| Othercashpaymentsrelatingtoinvestingactivities | 41,364,521.11 | |
| Totalcashoutflowsfrominvestingactivities | 162,199,880.27 | 767,795,821.96 |
| Netcashflowsfrominvestingactivities | -155,275,763.43 | -745,688,391.05 |
| III.Cashflowsfromfinancingactivities | ||
| Cashproceedsfrominvestmentsbyothers | 5,880,000.00 | |
| Incl:Cashreceiptsfromcapitalcontributionsfromnon-controllinginterestsofsubsidiaries | 5,880,000.00 |
| Cashreceiptsfromborrowings | 567,395,696.23 | 286,202,002.73 |
| Othercashreceiptsrelatingtofinancingactivities | 297,416,755.19 | 337,054,182.02 |
| Totalcashinflowsfromfinancingactivities | 870,692,451.42 | 623,256,184.75 |
| Cashrepaymentsfordebts | 177,254,802.73 | 142,100,000.00 |
| Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses | 59,139,307.66 | 64,675,017.27 |
| Incl:Dividendsorprofitpaidtonon-controllingshareholdersofsubsidiaries | 555,825.80 | 1,558,470.71 |
| Othercashpaymentsrelatingtofinancingactivities | 245,774,326.14 | 473,597,592.59 |
| Totalcashoutflowsfromfinancingactivities | 482,168,436.53 | 680,372,609.86 |
| Netcashflowsfromfinancingactivities | 388,524,014.89 | -57,116,425.11 |
| IV.Effectofforeignexchangeratechangesoncashandcashequivalents | -2,440.78 | 365.20 |
| V.Netincreaseofcashandcashequivalents | -73,503,188.56 | -1,491,078,299.59 |
| Add:Cashandcashequivalentsatbeginningoftheyear | 5,405,113,257.99 | 8,426,071,170.16 |
| VI.Cashandcashequivalentsatendofyear | 5,331,610,069.43 | 6,934,992,870.57 |
6.CashFlowStatementofParentCompany
InRMB
| Item | Currentperiod | Lastperiod |
| I.Cashflowsfromoperatingactivities: | ||
| Cashreceiptsfromthesaleofgoodsandtherenderingofservices | 1,022,932,449.00 | 1,062,518,589.11 |
| Write-backoftaxreceived | ||
| Othercashreceiptsrelatingtooperatingactivities | 14,576,152.93 | 22,736,474.18 |
| Totalcashinflowsfromoperatingactivities | 1,037,508,601.93 | 1,085,255,063.29 |
| Cashpaymentsforgoodsandservices | 1,132,644,884.96 | 1,207,589,273.35 |
| Cashpaymentstoandonbehalfofemployees | 41,055,249.91 | 39,968,369.74 |
| Paymentsofalltypesoftaxesandsurcharges | 12,594,584.85 | 20,509,993.91 |
| Othercashpaymentsrelatingtooperatingactivities | 5,207,747.54 | 14,820,413.79 |
| Totalcashoutflowsfromoperatingactivities | 1,191,502,467.26 | 1,282,888,050.79 |
| Netcashflowsfromoperatingactivities | -153,993,865.33 | -197,632,987.50 |
| II.Cashflowsfrominvestingactivities: | ||
| Cashreceiptsfromreturnsofinvestments | 2,997,441.73 | 13,636,447.00 |
| Cashreceiptsfromreturnsoninvestments | 3,599,555.61 | |
| Netcashreceiptsfromdisposaloffixedassets,intangibleassetsandotherlong-termassets | 233,663.00 | |
| Netcashreceivedfromdisposalofsubsidiariesandotherunits | ||
| Othercashreceiptsrelatingtoinvestingactivities | 721,955,173.97 | 602,709,245.48 |
| Totalcashinflowsfrominvestingactivities | 728,785,834.31 | 616,345,692.48 |
| Cashpaidforacquisitionoffixedassets,intangibleassetsandotherlong-termassets | 710,954.22 | 670,760.44 |
| Cashpaidforinvestment | ||
| Netcashreceivedfromsubsidiariesandotherunitsobtained | ||
| Othercashpaymentsrelatingtoinvestingactivities | 895,600,000.00 | 792,214,521.11 |
| Totalcashoutflowsfrominvestingactivities | 896,310,954.22 | 792,885,281.55 |
| Netcashflowsfrominvestingactivities | -167,525,119.91 | -176,539,589.07 |
| III.Cashflowsfromfinancingactivities | ||
| Cashreceivedfromabsorbing |
| investment | ||
| Cashreceiptsfromborrowings | 210,000,000.00 | 24,694,789.52 |
| Othercashreceiptsrelatingtofinancingactivities | 8,801,174,486.16 | 8,004,663,212.88 |
| Totalcashinflowsfromfinancingactivities | 9,011,174,486.16 | 8,029,358,002.40 |
| Cashrepaymentsfordebts | 22,594,789.52 | 12,100,000.00 |
| Cashpaymentsfordistributionofdividends,profitorinterestexpenses | 10,931,189.66 | 9,363,675.10 |
| Othercashpaymentsrelatingtofinancingactivities | 8,758,875,716.34 | 7,724,025,779.65 |
| Totalcashoutflowsfromfinancingactivities | 8,792,401,695.52 | 7,745,489,454.75 |
| Netcashflowsfromfinancingactivities | 218,772,790.64 | 283,868,547.65 |
| IV.Effectofforeignexchangeratechangesoncashandcashequivalents | -2,440.78 | 365.20 |
| V.Netincreaseofcashandcashequivalents | -102,748,635.38 | -90,303,663.72 |
| Add:Cashandcashequivalentsatbeginningoftheyear | 3,020,909,473.71 | 2,894,333,956.38 |
| VI.Cashandcashequivalentsatendofyear | 2,918,160,838.33 | 2,804,030,292.66 |
II.Explanationonfinancialstatementadjustment
1.Financialstatementadjustmentatthebeginningofthefirstyearwhenimplementationofnewleasingrulesfrom2021
□Applicable√Notapplicable
2.Retrospectiveadjustmentofthecomparativedataforinitialnewleasingrulesfrom2021
□Applicable√Notapplicable
III.Auditreport
Whetherthe1
stquarterlyreporthasbeenauditedornot
□Yes√No1QreportoftheCompanyisunaudited.
ChinaNationalAccordMedicinesCorporationLtd.
LegalRepresentative:LinZhaoxiong
24April2021